Zardaverine and aerosolised iloprost in a model of acute respiratory failure

European Respiratory Journal

Volumn 22, Issue 2, 2003, Pages 342-347

  Schermuly, Ralph T ^a   Leuchte, H ^a   Ghofrani, H A ^a   Weissmann, N ^a   Rose, F ^a   Kohstall, M ^a   Olschewski, H ^a   Schudt, C ^b   Grimminger, F ^a   Seeger, W ^a   Walmrath, D ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Altana Pharma   (Germany)

Author keywords

Multiple inert gas elimination technique; Phosphodiesterase; Prostacyclin; Rabbit; Zardaverine

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ILOPROST; INERT GAS; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; THROMBOXANE A2; ZARDAVERINE;

ACUTE RESPIRATORY FAILURE; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; EXPERIMENTAL ANIMAL; FEMALE; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG HEMODYNAMICS; LUNG PERFUSION; LUNG VENTILATION PERFUSION RATIO; MALE; MEDICAL NEBULIZER; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RABBIT; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADMINISTRATION, INHALATION; ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; RABBITS; RESPIRATORY DISTRESS SYNDROME, ADULT; VASODILATOR AGENTS;

EID: 10744233893     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00093802     Document Type: Article

References (30)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349.
2. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med 2001; 52: 221-237.
3. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993; 342: 961-962.
4. Radermacher P, Santak B, Becker H, Falke KJ. Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 1989; 70: 601-606.
5. Gallart L, Lu Q, Puybasset L, Umamaheswara Rao GS, Coriat P, Rouby JJ. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitrine Study Group. Am J Respir Crit Care Med 1998; 158: 1770-1777.
6. Lu Q, Mourgeon E, Law-Koune JD, et al. Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Anesthesiology 1995; 83: 929-943.
7. Michard F, Wolff MA, Herman B, Wysocki M. Right ventricular response to high-dose almitrine infusion in patients with severe hypoxemia related to acute respiratory distress syndrome. Crit Care Med 2001; 29: 32-36.
8. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-405.
9. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 1671-1677.
10. Fitscha P, Tiso B, Krais T, Sinzinger H. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD). Adv Prostaglandin Thromboxane Leukot Res 1987; 17: 450-454.
11. Hildebrand M. Pharmacokinetics of iloprost and cicaprost in mice. Prostaglandins 1992; 44: 431-442.
12. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-1870.
13. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolised prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824.
14. Schermuly RT, Ghofrani HA, Enke B, et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 1500-1506.
15. Schermuly RT, Roehl A, Weissmann N, et al. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000; 292: 512-520.
16. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-748.
17. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-370.
18. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266: 536-543.
19. Seeger W, Walmrath D, Grimminger F, et al. Adult respiratory distress syndrome: model systems using isolated perfused rabbit lungs. Methods Enzymol 1994; 233: 549-584.
20. Schermuly R, Schmehl T, Gunther A, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange. Am J Respir Crit Care Med 1997; 156: 445-453.
21. Schmehl T, Gebhart J, Schutte H, Scharmann A, Seeger W. On-line laser-photometric monitoring of aerosol deposition in ventilated rabbit lungs. J Appl Physiol 1996; 80: 351-356.
22. Wagner PD, Saltzman HA, West JB. Measurement of continuous distributions of ventilation-perfusion ratios: theory. J Appl Physiol 1974; 36: 588-599.
23. Wagner PD. Estimation of distributions of ventilation/perfusion ratios. Ann Biomed Eng 1981; 9: 543-556.
24. Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997; 10: 1084-1092.
25. Schudt C, Winder S, Forderkunz S, Hatzelmann A, Ullrich V. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol 1991; 344: 682-690.
26. Kilian U, Beume R, Eltze M, Schudt C. Is phosphodiesterase inhibition a relevant bronchospasmolytic principle? Agents Actions 1989; 28: 331-348.
27. Hoymann HG, Heinrich U, Beume R, Kilian U. Comparative investigation of the effects of zardaverine and theophylline on pulmonary function in rats. Exp Lung Res 1994; 20: 235-250.
28. Uhlig S, Featherstone RL, Held HD, Nusing R, Schudt C, Wendel A. Attenuation by phosphodiesterase inhibitors of lipopolysaccharide- induced thromboxane release and bronchoconstriction in rat lungs. J Pharmacol Exp Ther 1997; 283: 1453-1459.
29. Seeger W, Hansen T, Rossig R, et al. Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability- effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Microvasc Res 1995; 50: 1-17.
30. Suttorp N, Weber U, Welsch T, Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 1993; 91: 1421-1428.